Boditech Med Inc. Overview
Boditech Med is a Korean in-vitro diagnostics (IVD) manufacturer specialising in point-of-care (POC) fluorescence immunoassay. Its business is a classic razor/razor-blade model: compact readers (ichroma family) and automated cartridge analysers (AFIAS family) are placed in hospitals, clinics and laboratories, after which single-use test cartridges generate recurring revenue — cartridges accounted for roughly 79% of sales in 2026 (Butler.works segment data). The company sells around 100 cartridge types covering cardiac, inflammatory/infectious, diabetes, hormone, cancer, renal, vitamin D and therapeutic-drug-monitoring markers, exporting to roughly 120–130 countries; over 90% of consolidated revenue is exported. Historically strongest in emerging markets (MENA, Latin America, Asia, Africa), it is now pushing into developed Europe, Korean in-clinic testing, veterinary diagnostics and Chinese chronic-disease screening. It is profitable, net-cash and founder-controlled, but its operating margin has compressed from the 20%+ range to the mid-to-high teens as it invests in new platforms.
What the company does. Boditech Med develops, manufactures and sells POC IVD systems — instruments plus proprietary reagent cartridges — that return quantitative immunoassay results from small samples (finger-prick capillary blood, venous whole blood, plasma, serum, urine, stool) typically within roughly 10–15 minutes at or near the patient. The company states its systems can run on whole blood without centrifugation and that it produces key antigens and antibodies in-house, which it presents as a cost advantage (BioSpectator, Aug 2016 IR coverage). It also holds smaller positions in molecular diagnostics (compact real-time PCR and nucleic-acid extraction), haemoglobin measurement, and — since 2025–2026 — veterinary immunoassay, haematology and biochemistry.
Company's own characterisation. In its disclosures and investor-facing descriptions, the company describes itself as a point-of-care immunodiagnostics specialist with two core business lines — diagnostic cartridges and diagnostic instruments — selling roughly 100 cartridge types for infectious, diabetes, cardiovascular, cancer and hormone indications in about 130 countries; instruments serve as platforms for one-time-use cartridges, with ichroma models positioned for large hospitals and developing countries and AFIAS models as fully automated, user-friendly systems whose share of sales is rising (DART business section as summarised by Valueline, 2Q26 update).
Business model and revenue model.
Product revenue (dominant): Cartridges ~79%, immunoassay instruments ~16%, haemoglobin instruments ~4%, other ~2% (2026 basis, Butler.works). In 1Q24, cartridges were 85% and instruments plus other 15% (Yuanta Securities, Aug 2024).
Service/subscription/licensing: No material service, subscription or licensing revenue is disclosed. The company does sell to OEM/own-brand-label partners (e.g., Theradiag in France for TDM products; an unnamed global animal-health distributor) — this is still product revenue.
Installed-base economics: Instrument placements drive cartridge pull-through. In 1H26 the company installed 8,234 instruments (+12% YoY), including 7,017 ichroma/AFIAS units (+51% YoY vs 4,659) (company release, 30 Jul 2026).
Value chain position. Vertically integrated manufacturer: in-house biological raw materials (antigens/antibodies), assay development, cartridge and instrument manufacturing in Chuncheon (with production in Guangxi, China, and the US via Immunostics). Distribution is predominantly through local distributors in export markets; direct/near-direct selling in Korea; OEM channels in France (TDM) and for veterinary products; and a semi-finished-goods supply model in China via Joinstar, used because Chinese procurement rules under basic healthcare reform favour domestically produced goods (Yuanta, Aug 2024).
Customer types. Hospital emergency departments and wards, small and mid-sized clinics (notably Korean internal-medicine and family-medicine clinics), physician office labs, blood transfusion services (haemoglobin screening), public-sector tenders (e.g., Iran's blood transfusion organisation, 2016), veterinary clinics (from 2025), and OEM partners.
End-markets served. Cardiac emergency testing (troponin I, CK-MB, NT-proBNP, myoglobin, D-dimer, ST2), infection/sepsis (CRP, PCT), latent tuberculosis (IGRA-TB), diabetes (HbA1c, HOMA-IR/insulin), endocrinology and fertility (TSH, sex hormones), cancer screening (PSA, iFOB), nutrition (vitamin D), anaemia (Hemochroma PLUS), kidney injury (PENKID), biologic-therapy drug monitoring (infliximab, adalimumab and anti-drug antibodies), COVID-19 antigen/antibody (now minor), and companion-animal diagnostics.
Independent characterisation. Boditech is a high-gross-margin (~59%) niche immunoassay player whose franchise rests on low-cost, rugged fluorescence readers suited to resource-constrained settings. Its moat is breadth of menu and installed base in emerging markets rather than proprietary analyte IP. The strategic question for 2026–2028 is whether it can convert that emerging-market franchise into developed-market and new-category growth (Europe, Korean in-clinic testing, veterinary, China chronic disease) without permanently diluting its historic 20%+ operating margin. The post-COVID earnings base (FY2022–FY2025 operating profit KRW 24.7–28.9 bn) is stable but not yet growing in line with revenue.
Strategy
Stated strategic themes (company releases and management interviews 2024–2026, paraphrased):
-
Developed-market penetration — shift European mix toward Switzerland, Italy, Germany, France and the Czech Republic; pursue US FDA approval for core assays (vitamin D, HbA1c) and rebuild Americas presence.
-
Korea in-clinic testing — capture demand created by the specimen-testing outsourcing reform scheduled for December 2026 by offering immunoassay, biochemistry and haematology under one brand (CBChroma approval mid-2026).
-
Companion-animal diagnostics — enter via OEM supply to a global animal-health distributor and own-brand AFIAS-VET/VETCHROMA 3 sales across the US and Europe; KVMA MOU in Korea.
-
China chronic-disease monitoring — semi-finished cartridge supply to Joinstar for regional chronic-disease programmes under China's primary-care reform.
-
High-value menu expansion — TDM, latent TB, PENKID, ST2, HOMA-IR, vitamin D, cancer markers; expanding from ~90 to ~100+ assays.
-
Platform extension — from immunoassay into biochemistry, urinalysis, haematology and molecular.
-
Shareholder returns — regular buyback trusts and cancellation of treasury shares.
Initiatives announced or advanced in the last 24 months (Oct 2024 – Oct 2026)
ESG/sustainability commitments: None publicly disclosed in sources reviewed.
Cost programmes: None announced; management is instead investing ahead of revenue.
Medium-term financial targets / guidance: The company does not publish numerical guidance. Management has stated qualitatively (Jul 2026) that it expects growth and profitability to improve from 2H26 as new businesses enter markets. Historical targets were missed or abandoned (e.g., 2015 target of KRW 100 bn revenue by 2018 vs actual FY2018 revenue of KRW 66.2 bn; 2016 aim of balancing US, Japan and China at ~25% each by 2018–2019).
Products & Services
Pricing is not publicly disclosed for any product; one analyst estimated veterinary cartridge ASP at ~USD 4 (Yuanta, Aug 2024). Launch years are given only where verified.
Immunoassay instruments (platforms)
| Product | Description / capabilities | Target customer | Launch / status |
|---|---|---|---|
| ichroma (original) | Compact fluorescence immunoassay reader; manual cartridge workflow; the company's foundational platform | Hospitals, clinics, emerging markets | Early 2000s; flagship of China CRP franchise |
| ichroma II | Diagnostic immuno-analyser for cardiac, cancer, hormone, infectious, autoimmune and metabolic markers | Large hospitals, developing markets | In market |
| ichroma III | Higher-throughput analyser enabling simultaneous multi-parameter testing | Higher-volume labs/hospitals | In market |
| ichroma M2 / ichroma M3 | Portable analysers | Field, small clinics | In market |
| ichroma-50 | Automated high-throughput immunoassay system | Central labs, hospitals | In market |
| ichroma TRIAS | Ultra-high-sensitivity respiratory disease analyser (time-resolved fluorescence lineage) | Hospitals | In market |
| AFIAS-1 | Fully automated single-channel cartridge immunoassay analyser | Clinics, ED | In market; named as a core product in 2022 |
| AFIAS-3 | Automated 3-channel analyser | Clinics/hospitals | In market |
| AFIAS-6 | Automated 6-channel analyser | Hospitals, mid-volume labs | In market; core product |
| AFIAS-10 | Automated 10-channel analyser | Higher-volume hospitals | In market |
| AFIAS-50 | Automated high-throughput system used with AFIAS iFOB | Screening labs | FDA-cleared configuration for iFOB (c.2017) |
| Hemochroma PLUS | Handheld haemoglobin analyser for anaemia screening | Blood banks, transfusion services, clinics | In market since at least 2014; Korean Red Cross and Iran IBTO tenders |
| CBChroma | Haematology (complete blood count) analyser | Korean clinics (in-clinic testing) | Korean manufacturing approval mid-2026 |
| Biochemistry and urinalysis platforms | Clinical chemistry and urine testing to complete in-clinic menu | Korean clinics | Rolled out 2025–2026 |
Products listed in aggregator descriptions but not further verified: "ALFIAS-3" (likely an AFIAS variant/typo at source) and "SyncNeb".
Molecular diagnostics
| Product | Description | Status |
|---|---|---|
| ExAmplar | Compact real-time PCR system using ready-to-use cartridges for quantitative/qualitative virus and bacteria detection | In market |
| NuActor | Automated nucleic-acid extraction system | In market |
Reagents / cartridges (organised by clinical area)
| Area | Named markers / products (verified) | Notes |
|---|---|---|
| Cardiac | Troponin I (Tn-I), CK-MB, NT-proBNP, Myoglobin, D-Dimer, ST2 (cardiac risk) | Cardiovascular >KRW 18 bn revenue in FY2024 |
| Inflammation / sepsis | CRP, PCT (procalcitonin) | ichroma CRP described by company as largest-share product in China |
| Infectious disease | IGRA-TB (latent tuberculosis), COVID-19 antigen and antibody, Immunostics infectious tests | Latent TB a growth driver in Italy |
| Diabetes / metabolic | HbA1c, HOMA-IR (insulin resistance) | HbA1c under US FDA review (2025); China chronic-disease supply via Joinstar |
| Hormones | TSH (AFIAS TSH), sex/fertility hormones | Hormone tests raised ASP in 2016 |
| Cancer | PSA, AFIAS iFOB (colorectal screening) | Cancer +68% YoY in 2Q26 |
| Nutrition | Vitamin D | Launched 2016; one of the fastest-growing lines; under US FDA review (2025) |
| Renal | PENKID (proenkephalin, acute kidney injury prediction/monitoring) | High-value product |
| Therapeutic drug monitoring (TDM) | Infliximab, anti-infliximab, adalimumab, anti-adalimumab | CE-marked; OBL supply to Theradiag (ez-Track1); ~12-minute result |
| Autoimmune / rheumatology | Autoimmune markers | +24% in 2Q26 |
| Organ function | Organ-function markers | Listed in product catalogue categories |
| Women's health (US) | hCG pregnancy tests, FOB (Immunostics) | US subsidiary portfolio |
The menu has grown from 29 reagents (2015) to 44 (2017), 70+ (2022), 85–90+ biomarkers (2022–2023 company statements) and ~100 cartridge types (2026 business description).
Consumer / OTC
| Product | Description | Status |
|---|---|---|
| Swab-N-Go Home Test COVID-19 Ag | OTC rapid antigen home test produced/sold via Immunostics | FDA EUA 17 Jul 2023; distribution via CLIAwaived |
Veterinary diagnostics
| Product | Description | Status |
|---|---|---|
| AFIAS-VET | Fully automated veterinary immunoassay analyser | Showcased ADLM 2025 |
| VETCHROMA 3 | Manual/semi-automated veterinary immunoassay reader for the same uses | Showcased ADLM 2025 |
| Veterinary cartridges | Companion-animal immunoassays | Commercialisation via OEM with a global animal-health distributor and own channels; Korea KVMA MOU |
| Anivet (historic) | Pet CRP test planned for China | Announced 2016 |
Financial Narrative
All figures consolidated K-IFRS, fiscal years ending 31 December. Primary source: DART annual reports as compiled by ETFshopping (income statement FY2016–FY2025) and Valueline/DataHero (balance sheet FY2022–FY2025 and FY2025 detail).
Income statement
Revenue CAGR: FY2021–FY2025 (4 years): +0.7% p.a. (distorted by the COVID-inflated FY2021 base). FY2022–FY2025 (3 years): +11.1% p.a. FY2020–FY2025 (5 years): +2.4% p.a.
FY2025 cost structure detail (KRW bn, Valueline): SG&A 67.0 (41.4% of revenue), of which R&D expense 18.6, salaries 17.3, fees/commissions 10.9, advertising 2.3, depreciation 3.8, amortisation 1.1; cost-of-sales labour 22.6 and depreciation 5.2. Finance income 4.3 vs finance costs 4.3 (FX gains/losses roughly offsetting); equity-method losses 2.7; asset impairment 0.5; effective tax rate ~14%.
EBITDA (computed: operating income + depreciation + amortisation from cash-flow statement)
Valueline reports FY2025 EBITDA of KRW 37.8 bn (methodology difference).
Quarterly trajectory (preliminary DART disclosures)
Source: ETFshopping compilation of DART preliminary earnings filings. 1H26: revenue KRW 93.3 bn (+15.7%), operating income KRW 15.0 bn (-13.0%), net income KRW 16.9 bn (+14.9%) (Kormedi, Aug 2026). Note: one press report gave 1Q24 operating income as KRW 0.9 bn, which conflicts with the DART figure of KRW 5.9 bn; the DART figure is used.
Balance sheet
Source: Valueline/DataHero (DART-derived). Net debt = total borrowings less cash and short-term financial instruments; lease liabilities excluded. 30 Jun 2026: total assets KRW 303.6 bn; cash KRW 38.4 bn; ST financial instruments KRW 12.5 bn; borrowings KRW 16.2 bn; total equity KRW 261.4 bn; treasury stock reduced to KRW 3.0 bn after the February 2026 cancellation; BPS KRW 11,286. In addition to current liquidity, the company held ~KRW 44.0 bn of other long-term financial assets at FY2025 year-end.
Cash flow
Sources: FY2025 cash-flow lines from Valueline (TTM to Dec 2025 equals FY2025); dividends and buybacks from ETFshopping (DART-based). FCF computed as OCF minus PP&E and intangible capex. Alternative FCF figures: KRW -10.9 bn (ETFshopping) and KRW -6.0 bn (Valueline methodology). TTM 2Q26: OCF KRW 14.8 bn, PP&E capex KRW 35.4 bn, FCF ≈ KRW -21.3 bn.
Ratios (computed)
Method notes: ROIC = operating income × (1 – 14% FY2025 effective tax rate) ÷ (equity + borrowings – cash – ST financial instruments) at FY2025 year-end. Interest coverage uses FY2025 interest expense of KRW 0.41 bn. Net debt/EBITDA is not meaningful (net cash). Payout ratios from ETFshopping. Valueline reports ROE of 10.5% (TTM) and 5-year average ROE of 16.1%.
Commentary on trends, inflections and drivers
Revenue: COVID normalisation, then a genuine re-acceleration. FY2020–FY2021 revenue (KRW 144–158 bn) was inflated by COVID-19 antigen/antibody kits and related demand; FY2022 revenue fell 25% to KRW 118.1 bn as COVID products faded while core lines (ichroma II, AFIAS-1, AFIAS-6) continued growing (Medigate News, Aug 2022). Since then the non-COVID franchise has compounded at ~11% p.a., and FY2025 (KRW 162.1 bn, +17.3%) surpassed the pandemic peak — an important inflection because it shows the base business is now larger than the COVID-era total. Momentum carried into 2026: 2Q26 revenue of KRW 50.4 bn (+21.5%) was a record, driven by developed Europe (+67%), Korea (+44%) and Africa (+67%), partly offset by MENA (-6.2%).
Margins: gross margin stable, operating margin structurally lower. Gross margin has held at 59–62% for five years, indicating no significant price erosion in cartridges despite Chinese low-cost competition and a rising instrument mix. The compression is entirely below gross profit: SG&A rose from KRW 59.1 bn (TTM 1Q25) to KRW 75.9 bn (TTM 2Q26), with R&D up from KRW 17.5 bn to KRW 21.0 bn. Management attributes this explicitly to pre-emptive hiring and R&D for biochemistry, haematology and veterinary diagnostics, and HQ headcount grew 29% between FY2021 and FY2025 (466→601) while revenue per employee fell from KRW 300 m to KRW 250 m (separate basis). Payroll reached 20.5% of separate revenue in FY2025 versus 14.8% in FY2021. Management claims the build-out is entering a stabilisation phase and expects gradual margin recovery (company release, Jul 2026); this remains unproven.
Earnings quality and volatility. Net income has repeatedly diverged from operating income because of FX translation (the company is >90% export), equity-method results from minority investees, and fair-value movements in fund investments. 4Q25 net income was only KRW 1.4 bn on KRW 5.1 bn operating profit (equity-method losses and impairments), while 1Q26 net income of KRW 9.5 bn exceeded operating income by KRW 2.7 bn on non-operating gains. Investors should anchor on operating income and cash flow.
Balance sheet: conservative but cash has been redeployed. Leverage is negligible (liabilities ~15% of equity). However, net cash fell from KRW 53.1 bn (FY2023) to KRW 19.2 bn (FY2025) as the company bought land (book value of land rose from KRW 13.3 bn to KRW 29.8 bn in FY2025), raised PP&E capex to ~KRW 33 bn, took on ~KRW 11 bn of new long-term debt, invested in associates and funds (associates KRW 2.0 bn → KRW 19.3 bn over two years), and continued buybacks. Cash rebuilt to KRW 38.4 bn by June 2026.
Working capital: the main cash drag. The cash conversion cycle is long (~250–295 days), reflecting deliberate inventory build for 100+ SKUs across 120+ countries and long receivables in distributor markets. FY2025 receivables grew 27% and inventory 9%, absorbing ~KRW 14 bn of cash; in 1H26 receivables rose a further KRW 10.4 bn and inventories KRW 8.3 bn. Combined with capex, this produced negative FCF in FY2025 and TTM 2Q26 — the most important financial monitorable.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Product Lines
| Product line | 1Q2024 | 1H2026 |
|---|---|---|
Immunoassay cartridges (%) | 85 | 79 |
Immunoassay instruments (%) | 15 | 16 |
Haemoglobin diagnostic instruments (%) | — | 4 |
Other (%) | — | 2 |
Disease Category Details
| Disease category | YoY growth (%) |
|---|---|
Cancer | 68 |
Cardiovascular | 27 |
Rheumatology / autoimmune | 24 |
Infectious disease | 16 |
Hormone | 12 |
Other (incl. vitamin D, anaemia) | 7 |
Diabetes | negative (exact % not disclosed) |
Group Entities
| Entity | Country | Stake (%) | Nature | Latest total assets (KRW Bn) | Latest net income (KRW Bn) |
|---|---|---|---|---|---|
Immunostics Inc. | USA (New Jersey) | 100 (acquired 2016) | US manufacturing/distribution subsidiary | — | — |
Boditech (Guangxi) Biotechnology Co., Ltd. | China | 48.51 | Chinese production entity | 18.4 | 0.74 |
Boditech Med India Private Limited | India | 99.99 | Indian subsidiary | 6.79 | -0.28 |
Boditech Ventures Co., Ltd. | Korea | 91.7 | Corporate venture capital | 2.88 | -0.03 |
Odastone Bio Investment Association No. 1 | Korea | 62.9 | Investment partnership | 3.26 | -0.04 |
Insigna Inc. | — | 15.72 | Strategic investee | 10.4 | -2.18 |
EasyDiatec (이지다이아텍) | Korea | 13.9 | Diagnostics investee | 1.69 | -2.58 |
Ramedi-tech (라메디텍) | Korea (KOSDAQ 462510) | 6.82 | Laser medical device / laser lancet maker | 19.6 | -8.35 |
4TEEN4 Pharmaceuticals GmbH | Germany | 1.95 | Biotech investee | 68.9 | -23.0 |
MyFirstAsset First Class PE Fund 1-C-S | Korea | 24.68 | Private fund | 21.5 | 4.76 |
MyFirstAsset First Wish PE Fund 2A | Korea | 72.8 | Private fund | 3.83 | 0.53 |
MyFirstAsset First Magic PE Fund 2A | Korea | 100 | Private fund | 2.35 | 0.49 |
MyFirstAsset Suho PE Trust C-S | Korea | 73.11 | Private fund | 3.73 | 1.11 |
ChinMax Boditech (JV) | China | — | Distribution JV with Chinese distributor | — | — |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 157.7 | 118.1 | 134.2 | 138.2 | 162.1 |
Revenue growth YoY (%) | 9.4 | -25.1 | 13.7 | 2.9 | 17.3 |
Cost of sales (KRW Bn) | 59.3 | 47.2 | 53.3 | 56.4 | 66.1 |
Gross profit (KRW Bn) | 98.4 | 70.8 | 80.9 | 81.8 | 96.0 |
Operating income (KRW Bn) | 51.9 | 24.7 | 28.5 | 26.2 | 28.9 |
Pre-tax income (KRW Bn) | — | — | — | — | 27.8 |
Income tax (KRW Bn) | — | — | — | — | 3.9 |
Net income (KRW Bn) | 47.4 | 25.3 | 26.7 | 27.2 | 23.9 |
EPS basic (KRW) | 1,937 | 1,080 | 1,181 | 1,242 | 1,091 |
Dividend per share (KRW) | 200 | 150 | 200 | 150 | 150 |
Gross margin (%) | 62.4 | 60.0 | 60.3 | 59.2 | 59.2 |
Operating margin (%) | 32.9 | 20.9 | 21.2 | 18.9 | 17.9 |
Net margin (%) | 30.1 | 21.4 | 19.9 | 19.7 | 14.7 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) (FY2025)
| Metric | FY2025 |
|---|---|
Depreciation of PP&E (KRW Bn) | 8.8 |
Amortisation of intangibles (KRW Bn) | 1.3 |
EBITDA (KRW Bn) | 39.0 |
EBITDA margin (%) | 24.1 |
Financial Analysis
| Metric | 2Q23 | 3Q23 | 4Q23 | 1Q24 | 2Q24 | 3Q24 | 4Q24 | 1Q25 | 2Q25 | 3Q25 | 4Q25 | 1Q26 | 2Q26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 35.0 | 34.9 | 35.9 | 33.1 | 36.2 | 37.6 | 31.2 | 39.1 | 41.5 | 39.9 | 41.5 | 42.8 | 50.4 |
Operating income (KRW Bn) | 8.2 | 8.8 | 6.9 | 5.9 | 9.3 | 8.8 | 2.3 | 8.1 | 9.2 | 6.6 | 5.1 | 6.8 | 8.2 |
Net income (KRW Bn) | 6.5 | 9.4 | 6.5 | 6.5 | 9.8 | 6.1 | 6.3 | 7.3 | 7.5 | 7.8 | 1.4 | 9.5 | 7.4 |
Operating margin (%) | 23.4 | 25.2 | 19.2 | 17.8 | 25.7 | 23.4 | 7.4 | 20.7 | 22.2 | 16.5 | 12.3 | 15.9 | 16.3 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets (KRW Bn) | 195.7 | 227.9 | 254.7 | 281.6 |
Current assets (KRW Bn) | 117.3 | 138.7 | 135.8 | 122.6 |
Cash and equivalents (KRW Bn) | 26.3 | 42.5 | 47.9 | 19.6 |
Short-term financial instruments (KRW Bn) | 8.7 | 20.7 | 12.2 | 16.2 |
Trade receivables (KRW Bn) | 22.1 | 26.5 | 29.3 | 37.2 |
Inventories (KRW Bn) | 30.8 | 31.6 | 38.8 | 42.1 |
PP&E (KRW Bn) | 58.2 | 56.4 | 61.9 | 86.9 |
Goodwill and intangibles (KRW Bn) | 5.4 | 5.5 | 6.1 | 6.1 |
Investments in associates (KRW Bn) | 2.1 | 2.0 | 12.9 | 19.3 |
Short-term borrowings (KRW Bn) | 4.0 | 7.1 | 6.7 | 3.5 |
Current portion of long-term debt (KRW Bn) | 1.7 | 0.9 | 1.1 | 1.7 |
Long-term borrowings (KRW Bn) | 2.3 | 2.1 | 1.8 | 11.3 |
Total borrowings (KRW Bn) | 8.0 | 10.0 | 9.7 | 16.5 |
Net debt (KRW Bn; negative = net cash) | -26.9 | -53.1 | -50.5 | -19.2 |
Total liabilities (KRW Bn) | 20.8 | 30.5 | 31.6 | 37.5 |
Total equity (KRW Bn) | 174.8 | 197.4 | 223.1 | 244.2 |
Equity attributable to owners (KRW Bn) | 163.6 | 186.2 | 210.3 | 231.3 |
Treasury stock (KRW Bn) | -21.6 | -21.6 | -24.4 | -27.4 |
Working capital (KRW Bn) | 101.2 | 111.4 | 108.4 | 99.2 |
Book value per share (KRW) | 6,964 | 7,928 | 8,953 | 9,906 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW Bn) | — | — | — | — | 22.1 |
Capex — PP&E (KRW Bn) | — | — | — | — | 33.0 |
Capex — intangibles (KRW Bn) | — | — | — | — | 1.0 |
Free cash flow (KRW Bn) | — | — | — | — | -11.9 |
Dividends declared for fiscal year (KRW Bn) | 4.3 | 3.3 | 4.4 | 3.3 | 3.3 |
Treasury share purchases (KRW Bn) | 8.8 | 7.2 | 0.0 | 3.0 | 5.0 |
New long-term borrowings (KRW Bn) | — | — | — | — | 20.3 |
Repayment of long-term borrowings (KRW Bn) | — | — | — | — | 13.7 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE on average total equity (%) | — | — | 14.3 | 12.9 | 10.2 |
ROA on average total assets (%) | — | — | 12.6 | 11.3 | 8.9 |
ROIC after tax (%) | — | — | — | — | 11.1 |
Current ratio (x) | — | 7.28 | 5.09 | 4.96 | 5.24 |
Debt to equity (x) | — | 0.05 | 0.05 | 0.04 | 0.07 |
Total liabilities to equity (%) | — | 11.9 | 15.4 | 14.2 | 15.3 |
Asset turnover on average assets (x) | — | — | 0.63 | 0.57 | 0.60 |
Interest coverage, EBIT / interest expense (x) | — | — | — | — | 70.6 |
Days sales outstanding, year-end (days) | — | 68 | 72 | 77 | 84 |
Days inventory outstanding, year-end (days) | — | 239 | 216 | 251 | 232 |
Days payables outstanding, year-end (days) | — | 12 | 36 | 35 | 30 |
Cash conversion cycle (days) | — | 295 | 253 | 293 | 286 |
Dividend payout ratio (%) | 10 | 14 | 17 | 12 | 14 |
Revenue by Region (%)
| Region | FY2021 | 1Q2024 |
|---|---|---|
Europe (%) | 14.7 | 22 |
Asia excl. China (%) | 22.8 | 19 |
MENA (%) | 21.4 | 19 |
China (%) | 6.7 | 13 |
Latin America (%) | 22.6 | — |
Africa (%) | 8.8 | — |
Revenue by Region and Revenue by Region (%)
| Metric | FY2025 | TTM 2Q2026 |
|---|---|---|
Domestic (Korea) revenue (KRW Bn) | 13.1 | 15.8 |
Export revenue (KRW Bn) | 149.0 | 159.0 |
Export share (%) | 91.9 | 91.0 |
Revenue by Region
| Region | 1Q2024 | 2Q2024 | 3Q2024 | 2Q2026 |
|---|---|---|---|---|
Europe revenue (KRW Bn) | 7.3 | 8.0 | — | 14.1 |
MENA revenue (KRW Bn) | — | 7.3 | 10.1 | — |
Revenue by Region (%) (FY2012–FY2021)
| Metric | FY2012 | FY2015 | FY2016 | FY2021 |
|---|---|---|---|---|
China share of revenue (%) | 73 | 67 | 53 | 6.7 |
Share Price and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Year-end share price (KRW) | 10,250 | 20,500 | 16,780 | 13,120 |
Calendar-year price return (%) | — | 100.0 | -18.1 | -21.8 |
Year-end market cap (KRW Bn) | 240.7 | 481.5 | 394.1 | 308.1 |
Year-end P/B (x) | — | 2.59 | 1.87 | 1.33 |
P/E on year-end price (x) | — | — | — | 13.0 |
Dividend per share (KRW) | 150 | 200 | 150 | 150 |
Capital Markets
| Item | Value |
|---|---|
Share price | KRW 9,050 (Valueline close) |
52-week range | KRW 9,300 – 14,090 (to 13 Oct 2026; 15 Oct close implies a new low) |
Performance | 1 month -2.1%; 6 months -20.5%; 1 year -33.1% (to 13 Oct, ETFshopping); YTD 2026 about -28% |
Since end-2022 (≈3.8 years) | -11.7% (computed) |
Shares outstanding | 21.91 m |
Market cap | ~KRW 205.7 bn |
Enterprise value (computed) | ~KRW 171 bn = market cap + borrowings KRW 16.2 bn − cash KRW 38.4 bn − ST financial instruments KRW 12.5 bn (Jun 2026) |
P/E (TTM EPS KRW 1,140) | ~7.9x |
P/B (BPS KRW 11,286, Jun 2026) | ~0.80x |
EV/Sales (TTM revenue KRW 174.8 bn) | ~0.98x |
EV/EBITDA (TTM EBITDA ≈ KRW 36.7 bn computed) | ~4.7x (Valueline: 4.15x) |
Dividend yield | ~1.6% |
5-year averages (Valueline) | P/E 11.8x; P/B 1.80x; EV/EBITDA 6.7x |
Capital Markets — P/E
| Metric | Boditech Med | SD Biosensor | Seegene | i-SENS |
|---|---|---|---|---|
P/E (x) | 7.9 | — | 20.9 | — |
P/B (x) | 0.80 | 0.30 | 1.62 | 1.52 |
Dividend yield (%) | 1.6 | 3.35 | 3.73 | 0.56 |
Dividend History
| Fiscal year | DPS (KRW) | Record date | Payment date |
|---|---|---|---|
FY2016 | 100 | 31 Dec 2016 | 11 Apr 2017 |
FY2017 | 50 | 31 Dec 2017 | 13 Apr 2018 |
FY2018 | 50 | 31 Dec 2018 | 15 Apr 2019 |
FY2019 | 50 | 31 Dec 2019 | 17 Apr 2020 |
FY2020 | 200 | 31 Dec 2020 | 19 Apr 2021 |
FY2021 | 200 | 31 Dec 2021 | 11 Apr 2022 |
FY2022 | 150 | 31 Dec 2022 | 12 Apr 2023 |
FY2023 | 200 | 1 Apr 2024 | 22 Apr 2024 |
FY2024 | 150 | 1 Apr 2025 | 21 Apr 2025 |
FY2025 | 150 | 1 Apr 2026 | 20 Apr 2026 |
Analyst Conclusions
Management guidance. No quantitative guidance. Management expects existing-business competitiveness plus new-business market entry to lift both growth and profitability from 2H26 (company release, 30 Jul 2026).
Consensus growth expectations. No active consensus identified. On a mechanical basis, 1H26 revenue growth of 15.7% and TTM revenue of KRW 174.8 bn imply FY2026 revenue in the high-KRW 170 bn to low-KRW 180 bn range if 2H26 growth is similar — this is an illustration, not a forecast.
Bull case
-
Operating leverage after the investment phase: gross margin is intact at ~59%; if SG&A growth slows while revenue grows mid-teens, operating margin could revert toward the 20%+ achieved in FY2023 (21.2%), lifting operating income well above the KRW 26–29 bn plateau of FY2022–FY2025.
-
Multiple catalysts converging: Korean outsourcing reform (Dec 2026), Europe +67%, ichroma/AFIAS placements +51% in 1H26, plus optional upside from FDA clearances, veterinary OEM and Joinstar.
-
Deep value: ~0.8x book, ~8x earnings and ~4.7x EV/EBITDA versus 5-year averages of 1.8x, 11.8x and 6.7x, with net cash and active share cancellation.
Bear case
-
Margin compression is structural: operating income has not grown since FY2022 despite +37% revenue; new categories pit Boditech against much larger incumbents.
-
Cash generation is deteriorating: negative FCF in FY2025 and TTM 2Q26, rising receivables and inventory, and capital deployed into loss-making minority investees.
-
Emerging-market and FX fragility: MENA decline, LatAm stagnation and Chinese price competition could offset developed-market gains; ~92% export exposure.
Key catalysts and monitorables (next 12 months)
-
3Q26 results (expected early Nov 2026) and FY2026 preliminary results (expected Feb 2027): operating margin trajectory vs 16.3% in 2Q26.
-
Korean domestic revenue after the December 2026 reform; CBChroma and biochemistry adoption.
-
European growth sustainability; MENA stabilisation.
-
US FDA decisions on vitamin D and HbA1c.
-
Veterinary OEM revenue disclosure.
-
Joinstar/China chronic-disease volumes.
-
Working capital (receivables, inventory) and FCF turning positive.
-
Further buybacks/cancellations and FY2026 DPS (record date expected 1 Apr 2027).
-
Any rationalisation of minority investments.
Analyst verdict.
Boditech Med is a financially sound, founder-led niche IVD manufacturer whose core franchise — low-cost fluorescence immunoassay readers feeding high-margin cartridges — has proven resilient: it shed its COVID windfall, rebuilt organically at roughly 11% a year, and in FY2025 surpassed its pandemic-era revenue peak with gross margins unchanged near 59%. The installed-base data are encouraging, with ichroma/AFIAS placements up by half in 1H26, which should underpin cartridge revenue for years.
The investment debate is therefore not about the franchise's survival but about capital allocation and operating leverage. Since FY2022 revenue has grown by more than a third while operating income has stayed flat at KRW 25–29 bn; SG&A and R&D are absorbing all incremental gross profit; free cash flow has turned negative on capex, receivables and inventory; and part of the balance sheet has migrated into loss-making minority stakes and private funds that inject volatility into reported earnings. Management's thesis — that the new platforms (haematology, biochemistry, veterinary) are now built and will start contributing from 2H26 — is plausible, particularly in Korea where a regulatory change creates a clear demand window, but it is not yet visible in the numbers.
The market has priced in substantial scepticism: the stock trades below book value, near 8x trailing earnings and under 5x EV/EBITDA, with net cash and ongoing share cancellations. At these levels, modest evidence of margin stabilisation — for instance, operating margin returning toward 18–20% on mid-teens revenue growth, with positive free cash flow — would likely be sufficient to re-rate the shares, while continued compression would confirm a value trap. On balance, Boditech screens as an undervalued but "show-me" story: fundamentally cheap with real catalysts, contingent on management demonstrating within the next two to four quarters that growth investments convert into operating profit and cash rather than simply cost.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background / notes | Compensation |
|---|---|---|---|---|
Dr. Choi Eui-yul (최의열) | Co-founder, CEO and representative director | Since founding (1998) | Former Hallym University professor; postdoctoral research at Yale University; largest shareholder (21.31%) | Individual pay not disclosed (no individual above KRW 500 m reported in sources reviewed) |
Nam Ki-bong (남기봉) | — | — | Holds 2.43% — second-largest individual holding within the controlling group | — |
Kim Byung-chul (김병철) | — | — | 0.17% | — |
Kim Young-min (김영민) | — | — | 0.05% | — |
Lee Yun-seok (이윤석) | — | — | 0.03% | — |
Jeong Sung-wook (정성욱) | — | — | 0.02% | — |
Hwang Jung-jun (황정준) | — | — | 0.02% | — |
Kim Jin-soo (김진수) | — | — | 0.01% | — |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake (%) | As of | Source |
|---|---|---|---|
Choi Eui-yul (CEO) | 21.31 | Dec 2025 | FY2025 annual report via ETFshopping |
Controlling shareholder + related parties (12 persons) | 25.44 | Dec 2025 | same |
Kim Jae-hak and 11 related persons | 11.91 | 2,024 | — |
National Pension Service | 4.2 | Dec 2024 | ETFshopping |
Employee Stock Ownership Association | ~1.7–1.9 (376,488 shares) | 2,026 | Investing.com |
Foreign investors | ~2.4–2.5 | Aug–Dec 2024 | Yuanta; Shinhan |
Minority shareholders (14,965 holders) | 51.26 | Dec 2025 | ETFshopping |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | HQ | Relative positioning vs Boditech |
|---|---|---|---|
POC immunoassay (cardiac, inflammation) | Abbott (i-STAT, Afinion, legacy Alere) | US | Global scale and developed-market installed base; far larger |
POC immunoassay / cardiac | Roche Diagnostics (cobas POC portfolio) | Switzerland | Premium developed-market positioning |
POC immunoassay | Siemens Healthineers | Germany | Lab-to-POC breadth |
POC cardiac/BNP | QuidelOrtho (Triage) | US | Strong US ED presence |
POC immunoassay | Radiometer (AQT90) / Danaher | Denmark/US | High-end ED cardiac |
Haemoglobin | HemoCue (Radiometer/Danaher) | Sweden | Global haemoglobin leader; Boditech displaced it in a 2014 Korean Red Cross tender |
Low-cost fluorescence POC | Wondfo Biotech | China | Price competitor in emerging markets |
Low-cost fluorescence POC | Getein Biotech | China | Price competitor; China primary care |
Rapid diagnostics | SD Biosensor | Korea | Larger, broader rapid-test portfolio; loss-making after Meridian acquisition |
Molecular diagnostics | Seegene | Korea | Molecular (PCR) rather than immunoassay; Europe-heavy |
POC / blood glucose / CGM | i-SENS | Korea | Glucose-focused; POC sub-segment overlaps |
Veterinary diagnostics | IDEXX, Zoetis, Bionote | US / US / Korea | Incumbents in companion-animal POC; Boditech is a new entrant |
Peer Comparison FY2025
| Metric | Boditech Med | SD Biosensor | Seegene | i-SENS |
|---|---|---|---|---|
Revenue (KRW Bn) | 162.1 | 710.6 | 474.2 | 315.4 |
Revenue growth YoY (%) | 17.3 | 2.3 | 14.5 | 8.3 |
Operating income (KRW Bn) | 28.9 | -80.9 | 34.5 | 7.9 |
Operating margin (%) | 17.9 | -11.4 | 7.3 | 2.5 |
Net income (KRW Bn) | 23.9 | -513.4 | 48.4 | -6.7 |
R&D intensity (% of revenue) | 11.5 | — | — | — |
Market cap, Oct 2026 (KRW Bn) | 205.7 | 720.9 | 1,679.1 | 516.5 |
P/B (x) | 0.80 | 0.30 | 1.62 | 1.52 |



